tirzepatide cardiovascular outcomes trial 2024 In patients with type 2 diabetes and atherosclerotic disease, was noninferior to dulaglutide with respect to major cardiovascular events. ⁣, ⁣, Read the full SURPASS-CVOT tirzepatide cardiovascular outcomes trial results

I've lost 30 pounds since officially starting in June. Rita G., 71 Verified MDWatch member Getting started is simple Qualifying Medicare patients can get FDA-approved GLP-1s for as little as a $50 copay through the Bridge Program

Used together, their combined effect on neuroinflammatory tone may be more comprehensive than either achieves alone, helping to slow the inflammatory processes that accelerate neurodegeneration during and after the menopausal transition

The FDA labeling for Wegovy, Saxenda, and Zepbound includes warnings about monitoring for depression, suicidal thoughts, and suicidal behavior, which is particularly relevant for patients already taking antidepressants

The CBTmin occurs about 2 hours before the habitual wake time